1 Gandhi RT, Lynch JB and Del Rio C (2020) Mild or moderate Covid-19. N Engl J Med 383, 1757–1766.
2 Viner RM, Russell SJ, Croker H, Packer J, Ward J, Stansfield C, Mytton O, Bonell C and Booy R (2020) School closure and management practices during coronavirus outbreaks including COVID-19: a rapid systematic review. Lancet Child Adolesc Health 4, 397– 404.
3 Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei Y-Y et al. (2020) A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269.
4 Sperk M, van Domselaar R, Rodriguez JE, Mikaeloff F, S´a Vinhas B, Saccon E, So€nnerborg A, Singh Ket al. (2020) Utility of proteomics in emerging and re- emerging infectious diseases caused by RNA viruses. J Proteome Res 19, 4259–4274.
5 Kuroya M and Ishida N (1953) Newborn virus pneumonitis (type Sendai). II. The isolation of a new virus possessing hemagglutinin activity. Yokohama Med Bull 4, 217–233.
6 Shioda T, Iwasaki K and Shibuta H (1986) Determination of the complete nucleotide sequence of the Sendai virus genome RNA and the predicted amino acid sequences of the F, HN and L proteins. Nucleic Acids Res 14, 1545–1563.
7 Takeuchi H, Imamura K, Ji B, Tsukita K, Enami T, Takao K, Miyakawa T, Hasegawa M, Sahara N, Iwata N et al. (2020) Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice. NPJ Vaccines 5, 28.
8 Adderson E, Branum K, Sealy RE, Jones BG, Surman SL, Penkert R, Freiden P, Slobod KS, Gaur AH, Hayden RT et al. (2015) Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children. Clin Vaccine Immunol 22, 298–303.
9 Yonemitsu Y, Matsumoto T, Itoh H, Okazaki J, Uchiyama M, Yoshida K, Onimaru M, Onohara T, Inoguchi H, Kyuragi R et al. (2013) DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther 21, 707–714.
10 Tai JA, Chang CY, Nishikawa T and Kaneda Y (2019) Cancer immunotherapy using the Fusion gene of Sendai virus. Cancer Gene Ther 27, 498–508.
11 Shi Y, Inoue H, Wu JC and Yamanaka S (2017) Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov 16, 115–130.
12 Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, Yamamoto T, Hotta A, Kondo T, Kitaoka S, Ohta A et al. (2017) The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med 9, eaaf3962.
13 Vershkov D, Fainstein N, Suissa S, Golan-Lev T, Ben- Hur T and Benvenisty N (2019) FMR1 reactivating treatments in fragile X iPSC-derived neural progenitors in vitro and in vivo. Cell Rep 26, 2531–2539.e2534.
14 Okita K, Yamakawa T, Matsumura Y, Sato Y, Amano N, Watanabe A, Goshima N and Yamanaka S (2013) An efficient nonviral method to generate integration- free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells 31, 458–466.
15 Hoenen T, Watt A, Mora A and Feldmann H (2014) Modeling the lifecycle of Ebola virus under biosafety level 2 conditions with virus-like particles containing tetracistronic minigenomes. J Vis Exp 91, 52381.
16 Ianevski A, Giri AK and Aittokallio T (2020) SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res 48, W488– W493.
17 Hormi M, Birsen R, Belhadj M, Huynh T, Cantero Aguilar L, Grignano E, Haddaoui L, Guillonneau F, Mayeux P, Hunault M et al. (2020) Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML. Eur J Haematol 105, 588–596.
18 Li HO, Zhu Y-F, Asakawa M, Kuma H, Hirata T, Ueda Y, Lee Y-S, Fukumura M, Iida A, Kato A et al. (2000) A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol 74, 6564–6569.
19 Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC et al. (2016) Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381–385.
20 Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L, Burgstaller-Muehlbacher S, De Jesus PD, Teriete P, Hull MV et al. (2020) Discovery of SARS- CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586, 113–119.
21 Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, DeWald LE, Schornberg KL, Scully C et al. (2013) FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 5, 190ra179.
22 Kouznetsova J, Sun W, Mart´ınez-Romero C, Tawa G, Shinn P, Chen CZ, Schimmer A, Sanderson P, McKew JC, Zheng W and et al. (2014) Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect 3, e84.
23 Hoenen T, Groseth A and Feldmann H (2019) Therapeutic strategies to target the Ebola virus life cycle. Nat Rev Microbiol 17, 593–606.
24 Shiraki K and Daikoku T (2020) Favipiravir, an anti- influenza drug against life-threatening RNA virus infections. Pharmacol Ther 209, 107512.
25 Tang YQ, Ye Q, Huang H and Zheng WY (2020) An overview of available antimalarials: discovery, mode of action and drug resistance. Curr Mol Med 20, 583–592.
26 Sarzi-Puttini P, Ceribelli A, Marotto D, Batticciotto A and Atzeni F (2019) Systemic rheumatic diseases: from biological agents to small molecules. Autoimmun Rev 18, 583–592.
27 Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O’Meara MJ, Rezelj VV, Guo JZ, Swaney DL et al. (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459–468.
28 Sacco MD, Ma C, Lagarias P, Gao A, Townsend JA, Meng X, Dube P, Zhang X, Hu Y, Kitamura N et al. (2020) Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L. Sci Adv 6, eabe0751.
29 Vuong W, Khan MB, Fischer C, Arutyunova E, Lamer T, Shields J, Saffran HA, McKay RT, van Belkum MJ, Joyce MA et al. (2020) Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat Commun 11, 4282.
30 Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y, Szeto T, Zhang X, Tarbet B, Marty MT, Chen Y and et al. (2020) Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res 30, 678–692.
31 Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, Schulz L, Widera M, Mehdipour AR, Tascher G et al. (2020) Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587, 657–662.
32 Rut W, Groborz K, Zhang L, Sun X, Zmudzinski M, Pawlik B, Wang X, Jochmans D, Neyts J, Młynarski W et al. (2020) Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design. Sci Adv 6, eabd4596.
33 Galindo I, Garaigorta U, Lasala F, Cuesta-Geijo MA, Bueno P, Gil C, Delgado R, Gastaminza P and Alonso C (2020) Antiviral drugs targeting endosomal membrane proteins inhibit distant animal and human pathogenic viruses. Antiviral Res 186, 104990.
34 Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D and Kim S (2020) Identification of antiviral drug candidates against SARS-CoV-2 from FDA- approved drugs. Antimicrob Agents Chemother 64, e00819-20.
35 Weston S, Coleman CM, Haupt R, Logue J, Matthews K, Li Y, Reyes HM, Weiss SR and Frieman MB (2020) Broad anti-coronavirus activity of food and drug administration-approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo. J Virol 94, e01218-20.
36 Eyre NS, Kirby EN, Anfiteatro DR, Bracho G, Russo AG, White PA, Aloia AL and Beard MR (2020) Identification of estrogen receptor modulators as inhibitors of flavivirus infection. Antimicrob Agents Chemother 64, e00289-20.
37 Fan H, Du X, Zhang J, Zheng H, Lu X, Wu Q, Li H, Wang H, Shi Y, Gao G et al. (2017) Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium. Sci Rep 7, 41226.
38 Zhou Y, Hou Y, Shen J, Huang Y, Martin W and Cheng F (2020) Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov 6, 14.
39 Behjati S and Frank MH (2009) The effects of tamoxifen on immunity. Curr Med Chem 16, 3076– 3080.
40 Cerciat M, Unkila M, Garcia-Segura LM and Arevalo MA (2010) Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gamma-inducible protein-10 by astrocytes exposed to inflammatory challenge in vitro. Glia 58, 93–102.
41 Suuronen T, Nuutinen T, Huuskonen J, Ojala J, Thornell A and Salminen A (2005) Anti- inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells. Inflamm Res 54, 194–203.
42 Azizian H, Khaksari M, Asadikaram G, Sepehri G and Najafipour H (2018) Therapeutic effects of tamoxifen on metabolic parameters and cytokines modulation in rat model of postmenopausal diabetic cardiovascular dysfunction: role of classic estrogen receptors. Int Immunopharmacol 65, 190–198.
43 Smetana K Jr, Rosel D and Br A´ bek J (2020) Raloxifene and bazedoxifene could be promising candidates for preventing the COVID-19 related cytokine storm, ARDS and mortality. In Vivo 34, 3027–3028.
44 Darwish I, Mubareka S and Liles WC (2011) Immunomodulatory therapy for severe influenza. Expert Rev Anti Infect Ther 9, 807–822.
45 Omeragic A, Kara-Yacoubian N, Kelschenbach J, Sahin C, Cummins CL, Volsky DJ and Bendayan R (2019) Peroxisome proliferator-activated receptor- gamma agonists exhibit anti-inflammatory and antiviral effects in an EcoHIV mouse model. Sci Rep 9, 9428.
46 Luzi L and Radaelli MG (2020) Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic. Acta Diabetol 57, 759–764.
47 Takayama K (2020) In vitro and animal models for SARS-CoV-2 research. Trends Pharmacol Sci 41, 513–517.
48 Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, Nagata N, Sekizuka T, Katoh H, Kato F et al. (2020) Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci USA 117, 7001–7003.
49 Leist SR, Sch€afer A and Martinez DR (2020) Cell and animal models of SARS-CoV-2 pathogenesis and immunity. Dis Model Mech 13, dmm046581.
50 Hekman RM, Hume AJ, Goel RK, Abo KM, Huang J, Blum BC, Werder RB, Suder EL, Paul I, Phanse Set al. (2020) Actionable cytopathogenic host responses of human alveolar type 2 cells to SARS-CoV-2. Mol Cell 80, 1104–1122.e1109.
論文の公開元へ
